- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
In The Literature: Ramucirumab Improves OS in Advanced Gastric Cancer Patients
The study, published in Lancet Oncology, found that ramucirumab significantly improved survival by over 2 months.
A randomized, placebo-controlled, double-blind, phase 3 trial in advanced gastric cancer patients, compared ramucirumab (Cymraza) plus paclitaxel with placebo plus pacitaxel. The global phase 3 study, conducted in 170 centers across 27 countries in 4 continents, found ramucirumab, a VEGFR-2 antagonist antibody, improved survival by more than 2 months when combined with paclitaxel, compared with the placebo arm. Of the 665 patients aged 18 years or older, 330 were in the ramucirumab arm and 335 were in the placebo arm. Grade 3 or higher adverse events observed in the treatment arm included neutropenia, leucopenia, hypertension, fatigue, anaemia, and abdominal pain.
Trial number on ClinicalTrials.gov: NCT01170663
Link to the paper published in Lancet Oncology: http://bit.ly/1uJN54N
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Texas Oncology to Roll Out Canopy for ePROs After Head-to-Head Pilot
March 18th 2025Debra Patt, MD, PhD, MBA, executive vice president of Public Policy and Strategy for Texas Oncology, said the practice received positive feedback from nurses and patients during a pilot that concluded in February.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
